Research programme: cardiovascular disease therapy - Resverlogix

Drug Profile

Research programme: cardiovascular disease therapy - Resverlogix

Alternative Names: RVX-408

Latest Information Update: 16 Jan 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Resverlogix Corporation
  • Class Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 01 Jan 2015 No development reported - Preclinical for Cardiovascular disorders in USA (PO)
  • 19 Jan 2011 Preclinical development is ongoing in USA
  • 10 Dec 2007 The US FDA grants approval to Resverlogix to begin a phase I clinical trial for RVX 208
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top